S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
NASDAQ:ICVX

Icosavax (ICVX) Stock Forecast, Price & News

$7.75
-0.05 (-0.64%)
(As of 09/29/2023 ET)
Compare
Today's Range
$7.53
▼
$8.14
50-Day Range
$7.22
▼
$9.17
52-Week Range
$2.28
▼
$16.45
Volume
326,103 shs
Average Volume
307,286 shs
Market Capitalization
$387.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Icosavax MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
248.4% Upside
$27.00 Price Target
Short Interest
Bearish
3.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of Icosavax in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$305,799 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.31) to ($2.27) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

323rd out of 972 stocks

Biological Products, Except Diagnostic Industry

43rd out of 153 stocks

See Top Rated MarketRank™ Stocks Here

ICVX stock logo

About Icosavax (NASDAQ:ICVX) Stock

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington.

ICVX Price History

ICVX Stock News Headlines

September 19, 2023 | finance.yahoo.com
Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
August 15, 2023 | markets.businessinsider.com
Jefferies Reaffirms Their Buy Rating on Icosavax (ICVX)
October 1, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
August 14, 2023 | finance.yahoo.com
Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 8, 2023 | finance.yahoo.com
Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential
July 2, 2023 | finance.yahoo.com
Icosavax, Inc. (NASDAQ:ICVX) is largely controlled by institutional shareholders who own 53% of the company
June 20, 2023 | finance.yahoo.com
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults
June 15, 2023 | benzinga.com
Icosavax EVP Awarded $1.79M Worth of Stock Options
October 1, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
May 24, 2023 | finance.yahoo.com
Icosavax (ICVX) Up on Positive VLP Vaccine Candidate Data
May 23, 2023 | finance.yahoo.com
Why Shares of Icosavax Jumped on Tuesday
May 23, 2023 | msn.com
CohBar, Ocean Biomedical top healthcare gainers; NantHealth, Microbot among losers
May 23, 2023 | markets.businessinsider.com
Icosavax Touts Encouraging Early-Cut Data From Phase 1 Trial Of RSV Vaccine
May 22, 2023 | benzinga.com
Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
May 22, 2023 | finance.yahoo.com
Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock
May 11, 2023 | finance.yahoo.com
Should You Buy Icosavax (ICVX) Ahead of Earnings?
May 10, 2023 | finance.yahoo.com
Icosavax, Inc. (ICVX) Reports Q1 Loss, Lags Revenue Estimates
May 10, 2023 | finance.yahoo.com
Icosavax Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 8, 2023 | finance.yahoo.com
Icosavax, Inc. (ICVX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
April 25, 2023 | msn.com
Oppenheimer Reiterates Icosavax (ICVX) Outperform Recommendation
March 30, 2023 | finance.yahoo.com
Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 28, 2023 | finance.yahoo.com
Icosavax to Participate in the Upcoming Healthcare Conferences
February 24, 2023 | finance.yahoo.com
Icosavax, Inc. (NASDAQ:ICVX) insider upped their holding by 527% earlier this year
February 21, 2023 | finance.yahoo.com
Icosavax Granted FDA Fast Track Designation for IVX-A12
January 12, 2023 | finance.yahoo.com
Icosavax (NASDAQ:ICVX) adds US$100m to market cap in the past 7 days, though investors from a year ago are still down 38%
January 6, 2023 | finance.yahoo.com
Icosavax Provides Corporate Update and Anticipated Milestones for 2023
December 17, 2022 | reuters.com
ICVX.O - Icosavax Inc | Stock Price & Latest News | Reuters
See More Headlines
Receive ICVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Icosavax and its competitors with MarketBeat's FREE daily newsletter.

ICVX Company Calendar

Last Earnings
8/14/2023
Today
10/01/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ICVX
CUSIP
N/A
CIK
1786255
Web
icosavax.com
Phone
206-737-0085
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.00
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+248.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.33)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-91,760,000.00
Net Margins
N/A
Pretax Margin
-15,765.98%
Return on Equity
-43.36%
Return on Assets
-39.80%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
16.76
Quick Ratio
16.76

Sales & Book Value

Annual Sales
$580,000.00
Price / Sales
668.73
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.47 per share
Price / Book
1.42

Miscellaneous

Outstanding Shares
50,047,000
Free Float
34,738,000
Market Cap
$387.86 million
Optionable
Not Optionable
Beta
0.39
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Adam K. Simpson (Age 47)
    Pres, CEO, Co-Founder & Director
    Comp: $855.95k
  • Mr. Niranjan Kanesa-thasan M.D. (Age 62)
    Chief Medical Officer
    Comp: $641.55k
  • Dr. Cassia Cearley Ph.D. (Age 40)
    Treasurer & Chief Bus. Officer
    Comp: $632.15k
  • Mr. Neil King Ph.D.
    Chair of Scientific Advisory Board & Co-Founder
  • Dr. David Baker M.D.
    Ph.D., Co-founder & Member of Scientific Advisory Board
  • Mr. Thomas Joseph Russo C.F.A. (Age 51)
    Chief Financial Officer
  • Ms. Jennifer Raymond
    Sr. VP of Technical Operations
  • Mr. Douglas A. Holtzman M.P.H. (Age 58)
    Ph.D., Chief Scientific Officer
  • Ms. Elizabeth Bekiroglu (Age 53)
    Gen. Counsel & Corp. Sec.
  • Ms. Lori Stewart
    Sr. VP of People & Culture

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ICVX Stock - Frequently Asked Questions

Should I buy or sell Icosavax stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Icosavax in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ICVX shares.
View ICVX analyst ratings or view top-rated stocks.

What is Icosavax's stock price forecast for 2023?

1 equities research analysts have issued 12-month price targets for Icosavax's shares. Their ICVX share price forecasts range from $27.00 to $27.00. On average, they anticipate the company's share price to reach $27.00 in the next year. This suggests a possible upside of 248.4% from the stock's current price.
View analysts price targets for ICVX or view top-rated stocks among Wall Street analysts.

How have ICVX shares performed in 2023?

Icosavax's stock was trading at $7.94 at the beginning of the year. Since then, ICVX stock has decreased by 2.4% and is now trading at $7.75.
View the best growth stocks for 2023 here.

Are investors shorting Icosavax?

Icosavax saw a increase in short interest in September. As of September 15th, there was short interest totaling 1,190,000 shares, an increase of 10.2% from the August 31st total of 1,080,000 shares. Based on an average daily volume of 231,600 shares, the days-to-cover ratio is currently 5.1 days. Currently, 3.7% of the company's shares are short sold.
View Icosavax's Short Interest.

When is Icosavax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ICVX earnings forecast.

How were Icosavax's earnings last quarter?

Icosavax, Inc. (NASDAQ:ICVX) released its earnings results on Monday, August, 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.01.

What ETF holds Icosavax's stock ?

ETFMG Treatments Testing and Advancements ETF holds 14,037 shares of ICVX stock, representing 0.78% of its portfolio.

When did Icosavax IPO?

(ICVX) raised $150 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.

What is Icosavax's stock symbol?

Icosavax trades on the NASDAQ under the ticker symbol "ICVX."

How do I buy shares of Icosavax?

Shares of ICVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Icosavax's stock price today?

One share of ICVX stock can currently be purchased for approximately $7.75.

How much money does Icosavax make?

Icosavax (NASDAQ:ICVX) has a market capitalization of $387.86 million and generates $580,000.00 in revenue each year. The company earns $-91,760,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis.

How can I contact Icosavax?

The official website for the company is icosavax.com. The company can be reached via phone at 206-737-0085 or via email at ir@icosavax.com.

This page (NASDAQ:ICVX) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -